Use of a Commercially Available Microarray to CharacterizeAntibiotic-Resistant Clinical Isolates of Klebsiella pneumoniae
Journal article, Peer reviewed
Accepted version
![Thumbnail](/oda-xmlui/bitstream/handle/10642/5270/Acceptedmanuscript.pdf.jpg?sequence=5&isAllowed=y)
View/ Open
Date
2017Metadata
Show full item recordCollections
Original version
Charnock C, Samuelsen Ø, Nordlie A, Hjeltnes B. Use of a Commercially Available Microarray to CharacterizeAntibiotic-Resistant Clinical Isolates of Klebsiella pneumoniae. Current Microbiology. 2017 http://doi.org/10.1007/s00284-017-1361-4Abstract
commercially available microarray (IDENTIBAC
AMR-ve) for the detection of antibiotic resistance
determinants was investigated for its potential to genotype
30 clinical isolates and two control strains of Klebsiella
pneumoniae. Resistance profiles and the production of
extended-spectrum b-lactamases were determined by disc
diffusion and the results were compared with the
microarray profiles in order to assess its scope and limitations.
Genes associated with resistance to a wide range of
antibiotics, including current first line therapy options,
were detected. In addition, the array also detected class 1
integrases. The array is easy to use and interpret, and is
useful in providing a general description of the numbers
and types of resistance determinants in K. pneumoniae. It
also provides an indication of the potential for resistance
gene acquisition. However, in most instances detected
resistance to specific antibiotics could not unequivocally be
assigned to hybridization with a specific array probe. We
conclude that the microarray is a valuable and rapid means
of investigating the presence of resistance gene classes of
therapeutic importance. It can also provide a starting point
for selecting analyses of greater resolving power, such as
phylogenetic subtyping by PCR sequencing.